New Antiangiogenetic Therapy Beyond Bevacizumab in the Treatment of Advanced Non Small Cell Lung Cancer

Author(s): Paola Claudia Sacco, Paolo Maione, Antonio Rossi, Assunta Sgambato, Francesca Casaluce, Giovanni Palazzolo, Cesare Gridelli

Journal Name: Current Pharmaceutical Design

Volume 21 , Issue 32 , 2015

Become EABM
Become Reviewer


Lung cancer is the leading cause of death from cancer worldwide with limited available treatment options in absence of specific molecular alteration. New therapeutic approaches for addressing non small cell lung cancer (NSCLC) are urgently needed. Angiogenesis plays a central role in the tumor growth and metastatic dissemination which stimulates multiple cells to build new abnormal microvessels and leads to tumor microenvironment alterations. This process involves many factors, such as, the vascular endothelial growth factor (VEGF) that has a dominant role, the fibroblast growth factors (FGFs) and the plateled-derived growth factor (PDGF) that together contribute to resistance to VEGF/VEGFR- directed therapy. To date, bevacizumab is currently the only angiogenesis inhibitor that has been approved for the treatment of patients with advanced NSCLC in first-line setting. Moreover, in the last year, two new antiangiogenic agents have been approved for the treatment of patients with advanced NSCLC in second line setting. This review describes the new antiangiogenic agents in the treatment of advanced NSCLC.

Keywords: Angiogenesis, bevacizumab, multi-target inhibitors, non-small cell lung cancer, targeted therapy, VEGF.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [4763 - 4772]
Pages: 10
DOI: 10.2174/1381612821666150729120009
Price: $65

Article Metrics

PDF: 49